TRACON Pharmaceuticals, Inc. Common Stock (TCON)

TCON was delisted on the 27th of June, 2024.

• Market cap: $3.83M
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies.

Employees: 17